Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Elacestrant in HR+/Her2- Breast Cancer Brain Metastasis
NCT04791384Phase 2Terminated
- Sponsor
- Criterium
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib and elacestrant in breast cancer, sponsored by Criterium. Primary endpoints: Adverse Events at 1.5 years and Efficacy of the drug combination at 2.5 years. Started Apr 2022; status: terminated.
02
Drugs
abemaciclibelacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04791384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791384.